Table 3.
Subjects' medical characteristics (n=146).
| Medical Characteristics | n (%) / Median (min-max) |
|---|---|
| Onset of Epilepsy (year) | 17.5 (1-74) |
| Duration of Epilepsy (year) | 11 (0.5-55) |
| Seizure Frequency (times) | 1 (0-52) |
| Seizure Type | |
| Focal Onset | 143 (97.9) |
| Generalized Onset | 3 (2.1) |
| Epileptic focality from EEG | |
| Right | 61 (41.8) |
| Left | 60 (41.1) |
| Focal Bilateral | 15 (10.3) |
| General | 3 (2.1) |
| No data | 7 (4.8) |
| Epilepsy Syndrome (n=139) | |
| Temporal | 96 (65.8) |
| Extratemporal | 40 (27.4) |
| Generalized | 3 (2.1) |
| No data | 7 (4.8) |
| AED Administered | |
| 1 AED | 95 (65.1) |
| 2 AED | 40 (27.4) |
| ≥ 3 AED | 11 (7.5) |
| Etiology of Epilepsy | |
| Genetic | 3 (2.1) |
| Unknown Etiology | 63 (43.2) |
| Structural | 80 (54.7) |
| (i) Hippocampal atrophy/sclerosis | 37 (46.3) |
| (ii) Other Structural Abnormalities | 43 (53.7) |
| Type of AED | |
| Valproate | 42 (28.8%) |
| Carbamazepine | 46 (31.5%) |
| Levetiracetam | 10 (6.8%) |
| Phenytoin | 43 (29.5%) |
| Clobazam | 31 (21.2%) |
| Phenobarbital | 31 (21.2%) |
| Clonazepam | 1 (0.7%) |
| Lamictal | 1 (0.7%) |
| Topiramate | 2 (1.4%) |